Abcellera Biologics 

Yahoo Finance • 11 days ago

TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 11, TD Cowen reiterated its Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), without giving a price target.... Full story

Yahoo Finance • last month

KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth

As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite hitting all-time highs, investors are increasingly optimistic about future growth prospects. In this context, penny stocks—th... Full story

Yahoo Finance • 2 months ago

AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone

Earnings Call Insights: AbCellera Biologics Inc. (ABCL) Q2 2025 MANAGEMENT VIEW * CEO Carl L.G. Hansen announced, "This quarter, we achieved a major company milestone, receiving Health Canada authorization to initiate AbCellera's first... Full story

Yahoo Finance • 2 months ago

Curious about the stocks that are showing activity after the closing bell on Thursday?

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MRM [https://www.chartmill.com/stock/quote/MRM/profile] 56.67% ME... Full story

Yahoo Finance • 2 months ago

Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an ‘Outperform’ rating and a $5 price target. The research firm remains confident... Full story

Yahoo Finance • 2 months ago

Abcellera Biologics stock hits 52-week high at $4.46

Abcellera Biologics Inc. stock reached a 52-week high, hitting $4.46, showcasing a significant milestone for the company. With a market capitalization of $1.33 billion, the biotech company maintains strong liquidity, as evidenced by its im... Full story

Yahoo Finance • 3 months ago

Abcellera Biologics stock hits 52-week high at 4.09 USD

Abcellera Biologics Inc. (ABCL) stock reached a 52-week high, trading at 4.09 USD. This milestone comes as the company experiences a significant 1-year change, with its stock appreciating by 46%. According to InvestingPro data, technical i... Full story

Yahoo Finance • 3 months ago

Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), lowering the pr... Full story

Yahoo Finance • 3 months ago

Leerink Partners assumes coverage on AbCellera stock with Outperform rating

Investing.com - Leerink Partners has assumed coverage on AbCellera Biologics (NASDAQ:ABCL) with an Outperform rating and a $5.00 price target, according to a research note released Monday. The stock has shown strong momentum recently, gain... Full story

Yahoo Finance • 4 months ago

AbCellera Biologics Inc. (ABCL): A Bull Case Theory

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share was trading at $2.14 as of 2... Full story

Yahoo Finance • 4 months ago

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Investors were surely discovering drug discovery company AbCellera Biologics(NASDAQ: ABCL) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by... Full story

Yahoo Finance • 4 months ago

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potenti... Full story

Yahoo Finance • 5 months ago

Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against other best Canadian penny stocks to invest in now.... Full story

Yahoo Finance • last year

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Are you a successful asset manager who has already amassed more than $1 billion in personal wealth? If not, there are probably a few things you can learn from the small list of folks who have. Luckily for us everyday investors, the Securi... Full story

Yahoo Finance • 2 years ago

Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks

In this article, we will take a detailed look at Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks. For a quick overview of such stocks, read our article Billionaire Investor Stan Druckenmiller and Inside... Full story

Yahoo Finance • 2 years ago

AbCellera Announces Resignation of Board Member

VANCOUVER, British Columbia, February 23, 2024--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effe... Full story

Yahoo Finance • 2 years ago

16 Best Penny Stocks To Buy For 2024

In this article, we will take a detailed look at the16 Best Penny Stocks To Buy For 2024. For a quick overview of such stocks, read our article 5 Best Penny Stocks To Buy For 2024. The stock market’s optimism wave recently saw a break aft... Full story

Yahoo Finance • 2 years ago

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

New data from AbCellera’s T-cell engager platform demonstrates that diverse CD3-binding antibodies enable optimization of T-cell engager function beyond what is possible by modifying a single CD3-binder VANCOUVER, British Columbia, Novemb... Full story

Yahoo Finance • 2 years ago

AbCellera Reports Q3 2023 Business Results

Total revenue of $7 million, compared to $101 million in Q3 2022 Total cumulative partnered program starts of 110, up 20% from Q3 2022 Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 pe... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

WILMINGTON, Del. & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discov... Full story